1h Free Analyst Time
Sickle-cell anemia treatment is associated with high cost medications in the US. To reduce the treatment burden on the patients, several companies and government organizations are offering reimbursement for the treatment. Several stakeholders are offering partnerships to work with state and local policyholders and the payer group to ensure the payment and reimbursement are in place so that the providers can be supported to advance access to quality care. The analysts have predicted that the sickle-cell anemia therapeutics market in the US will register a CAGR of over 15% by 2022.
Speak directly to the analyst to clarify any post sales queries you may have.
Market Overview
Recent product approvals for sickle-cell anemia
Due to fewer product availability in the US for the treatment of sickle-cell anemia, hence these recently approved products drive the market over the forecast period.
Limited number of approved drugs
The availability of very limited approved therapies for the treatment of sickle-cell anemia id the US is expected to hamper the growth of the market during our forecast period.
For the detailed list of factors that will drive and challenge the growth of the sickle-cell anemia therapeutics market in the US during the 2018-2022, view this report.
Competitive Landscape
The sickle-cell anemia therapeutics market in the US is highly concentrated. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Table of Contents
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORTPART 03: RESEARCH METHODOLOGYPART 08: CUSTOMER LANDSCAPEPART 09: DECISION FRAMEWORK
PART 04: MARKET LANDSCAPE
PART 05: MARKET SIZING
PART 06: FIVE FORCES ANALYSIS
PART 07: MARKET SEGMENTATION BY THERAPY
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
List of Exhibits
Executive Summary
Sickle-Cell Anemia Therapeutics Market in the US 2018-2022The analyst recognizes the following companies as the key players in the sickle-cell anemia therapeutics market in the US: Bristol-Myers Squibb, Emmaus Medical, Medunik USA.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the research on the development of gene therapy to treat sickle-cell anemia is a new approach.
According to the report, one of the major drivers for this market is the awareness’s programs are expected to increase the focus on disease diagnosis and treatment options. Therefore, leading to the growth of the sickle-cell anemia therapeutics market in the US over the forecast period.
Further, the report states that one of the major factors hindering the growth of this market is the stringent government regulations for marketing approval are expected to restrict the market growth during the forecast period.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned
A selection of companies mentioned in this report includes:
- Bristol-Myers Squibb
- Emmaus Medical
- Medunik USA